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Background: Although surgical resection is considered the standard of care for early-stage non-small cell
lung cancer, radiotherapy [stereotactic body radiation therapy (SBRT)] has been proposed as a minimally
invasive treatment alternative. Studies have not examined differences in quality of life (QoL) between surgery
and radiotherapy, despite important implications for patient and provider decision making.
Methods: The Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey (1998–2014)
was used to assess changes in physical QoL score [Physical Component Summary (PCS)] and mental health
QoL score [Mental Component Summary (MCS)] from baseline (prior to cancer diagnosis) to follow-up after
treatment with surgery only or radiotherapy only. QoL was measured using the 36-item Short Form Health
Survey (SF-36) until 2006, when it was replaced by the Veterans RAND 12-Item Health Survey (VR-12).
Results: Data from 184 patients (28 SBRT, 156 surgery) was included. There was a significant decline in
PCS score from baseline to follow-up (surgery: −4.81; 95% CI: −6.31, −3.30; P<0.0001; SBRT: −5.6; 95%
CI: −9.96, −1.24; P=0.0137). Similarly, MCS scores declined for both groups although the change was significant
for surgery patients only (surgery: −2.96; 95% CI: −4.55, −1.37; P=0.0003; SBRT: −1.86; 95% CI: −5.4, 1.68;
P=0.2902). Surgical patients had higher baseline PCS (P=0.0061) and MCS (P=0.0056) than SBRT patients.
There was no significant difference in the change over time between the two treatment options for PCS or MCS.
Conclusions: Although both treatments negatively impact QoL, the impact of SBRT on QoL may be
comparable to surgery and therefore SBRT should be given consideration as an alternative treatment,
especially when surgery is not an option.
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Introduction
Surgical resection has been considered the standard of care
and most effective treatment for early-stage non-small cell
lung cancer (NSCLC) (1,2). However, approximately 25%
of early-stage NSCLC patients do not undergo surgery
due preexisting comorbidities, older age, or refusal (1,3).
stereotactic body radiation therapy (SBRT), also known
as stereotactic ablative radiotherapy (SABR), has been
proposed in order to provide a minimally invasive treatment
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that improves accuracy in delivering ultra-high radiation
doses (4). SBRT has become accepted and adapted as an
alternative treatment for early-stage NSCLC (5-11).
To date, there is no consensus on the comparative
effectiveness of SBRT versus surgery (12-14). Two randomized
controlled trials [STARS (15) and ROSEL (16)] attempted
to compare SBRT and surgery in the treatment of NSCLC,
however, both trials were closed early due to low recruitment.
A pooled analysis of these two trials suggested a better
3-year survival with SBRT in comparison to surgery (5).
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However, a meta-analysis comparing the effectiveness of
SBRT and surgical resection in early-stage NSCLC found
that 3-year survival of sublobar resection (SLR) and SBRT
were comparable (6). Several retrospective studies have reported
comparable outcomes between surgery and SBRT (7-10).
Early-stage NSCLC patients receiving SBRT may differ
from patients eligible for surgery: they tend to be older,
have more comorbidities and lower baseline health-related
quality of life (HRQoL) than surgical patients (9,16,17).
The toxicity associated with SBRT and its appropriateness
for elderly patients or less healthy patients is still a topic
of debate (7,8,17-20). Similarly, there remains a lack of
consensus surrounding HRQoL after surgery for earlystage NSCLC. Several studies have found a decrease
in post-operative HRQoL compared with pre-operative
levels (21-23). However, others report that deficits in
HRQoL increase in the long-term beyond baseline levels (22).
While an abundance of literature focuses on the comparative
effectiveness of surgery versus SBRT (7-10,13-16)
and the impacts of each individually on HRQoL (20-27), no
studies, to our knowledge, have examined the differences in
quality of life (QoL) between SBRT and surgery in earlystage NSCLC patients. The high incidence and improved
survival for NSCLC necessitate a close examination of
potential differential QoL between surgery and SBRT in
early-stage NSCLC patients, as many early-stage survivors
are able to live long lives post-treatment. Coupled with the
unique challenges faced by lung cancer survivors including
physical (22,28-32) and mental health difficulties (32-36),
differential QoL between the two treatment options could
have important implications for patient and provider
decision-making (37).
We hypothesize that SBRT will confer less of a negative
impact on physical HRQoL from pre- to post-treatment as
compared to surgery overall given the more invasive nature
of surgery. However, our previous work has indicated that
early-stage NSCLC SLR patients show very little HRQoL
changes as compared to slight decrease from pre- to postsurgery in physical HRQoL among lobectomy patients
(21,31). Therefore, we hypothesize that surgical patients and
SBRT patients will both demonstrate decreases in physical
HRQoL, however, within surgical patients, lobectomy
patients will demonstrate worse physical HRQoL decreases
as compared to SLR patients. Further, we expect that SLR
patients will demonstrate similar decreases in HRQoL
to SBRT patients. Based on previous research, we do not
expect to see significant changes in mental HRQoL in
either the surgical or SBRT patients.
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Methods
Data source and patient population
This study used the Surveillance, Epidemiology, and End
Results Medicare Health Outcomes Survey (SEER-MHOS)
data set. Starting in 1998, the Center for Medicare and
Medicaid Services has annually surveyed approximately
1,000 to 1,200 randomly selected beneficiaries from each
participating managed care organization in the Medicare
Advantage program, in order to gather clinically meaningful
data on health outcomes, including functional status,
comorbid conditions, and HRQoL. Selected beneficiaries
are administered a baseline survey, and a follow-up survey
2 years later (38). This data was later linked to SEER,
allowing for assessment of HRQoL in relation to cancer
diagnoses and treatments. The Icahn Medical School at
Mount Sinai Review Board for Health Sciences Research
considered this study exempt because it relies on existing
data without patient identifiers.
SEER-MHOS was queried from 1998 to 2014 for
all patients with a first primary diagnosis of lung cancer,
with surveys before and after treatment for first cancer
diagnosis. Because some beneficiaries may have been
selected for more than one MHOS cohort, in some cases
the first survey was the follow-up from the earlier cohort,
while the second survey was the baseline from a later
cohort. For our purposes, baseline survey refers to the
most recent survey prior to diagnosis and treatment and
the follow-up survey refers to first survey after treatment.
Those with a gap between surveys longer than ~2.5 years
were excluded. Analysis was limited to patients with a
microscopically confirmed diagnosis of a stage 0 or I lung
cancer, who underwent only surgery or SBRT (n=184) (See
supplementary appendix online for Figure S1 which contains
the complete selection criteria).
Outcomes
HRQoL was measured using the 36-item Short Form
Health Survey (SF-36) until 2006, when it was replaced
by the Veterans RAND 12-Item Health Survey (VR-12)
instrument. Physical Component Summary (PCS) and
Mental Component Summary (MCS) scores were calculated
based on individual subscale scores (including physical
functioning, physical role limitation, pain, general health,
emotional well-being, emotional role limitation, social
functioning, and energy). The PCS and MCS scores have
been normalized to the 1990 US general population (mean
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Figure 1 Change over time in PCS and MCS scores in surgery and SBRT groups. PCS, Physical Component Score; MCS, Mental
Component Score; SBRT, stereotactic body radiation therapy.

± standard deviation, 50±10) and rescored to be equivalent
across all cohorts/years of data collection.
Statistical analyses
Continuous variables (PCS and MCS) are reported as means
and standard deviations, while categorical variables (all
covariates) are reported as percentages. Differences between
the two treatment groups at baseline were compared using χ2
tests (or Fisher’s exact test, where appropriate) for categorical
variables and t-tests for continuous variables. Paired t-tests
were used to assess changes over time in PCS and MCS
scores from baseline to follow-up within each treatment
group. Univariate and multivariate repeated measures
analysis of variance (ANOVA) were performed to compare
the change over time in the SBRT and surgery groups, by
evaluating the interaction between treatment and time. This
analysis was repeated to compare the sub-group of patients
who underwent either lobectomy or SLR. Additionally, the
analysis was repeated among those who underwent SLR
or SBRT, since these two treatments are sometimes seen
as alternatives for patients with poorer baseline health.
All analyses were adjusted for age at diagnosis, gender,
race, highest level of education attained, smoking status,
and whether each survey was completed by proxy. When
there was a significant difference in the presence of a
comorbidity between the groups, the analysis was adjusted
for the presence of that comorbidity. Comorbidities were
assessed using the MHOS survey questions, and included
hypertension (HTN), angina pectoris/coronary artery
disease (CAD), congestive heart failure (CHF), myocardial
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infarction, stroke, emphysema/asthma/chronic obstructive
pulmonary disease (COPD), and diabetes. For covariates
with missing or unknown values, a “missing” category was
created so as not to exclude those patients in multivariable
analyses. Surgical and SBRT groups were also compared
using a 1:1 propensity score matching with the Greedy
algorithm on age at diagnosis, gender, race, education,
baseline smoking status, completion of survey by proxy,
and presence of emphysema/asthma/COPD, and angina
pectoris/CAD. All statistical analyses were conducted using
SAS software (version 9.4, SAS Institute Inc., Cary, NC). All
P values are derived from two-tailed tests.
Results
There were 184 patients (28 with SBRT, 156 with surgery)
who matched the selection criteria. The average time
between surveys was 2.0 years (range, 0.8–2.3 years). The
baseline surveys were completed, on average, 1 year before
diagnosis and treatment (range, 0.02–2.12 years) and the
follow-up surveys 1 year after diagnosis (range, 0.04–
2.12 years). This did not significantly differ between the
two groups (i.e., surgery and SBRT). Patients from both
groups experienced a significant decline in PCS score, of
−4.81 from the baseline to follow-up in surgery patients
(95% CI: −6.31,−3.30; P<0.0001), while SBRT patients
experienced a change of −5.6 (95% CI: −9.96, −1.24;
P=0.0137). For MCS scores, surgery patients experienced
a change of −2.96 (95% CI: −4.55, −1.37; P=0.0003), while
SBRT patients experienced a non-significant change of
−1.86 (95% CI: −5.4, 1.68; P=0.2902) (Figure 1). There
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were significant differences in baseline PCS (P=0.0061) and
MCS (P=0.0056) values between patients who underwent
surgery and those who underwent SBRT, with those in
the surgery group having higher baseline values for both.
Patients in the SBRT group were older, with lower levels
of education, though not significantly. Patients treated
with SBRT were significantly more likely to have reported
COPD, emphysema, or asthma (P<0.0001), and angina
pectoris/CAD (P=0.0108).
Both the univariate and multivariate analyses revealed no
significant difference in the change over time between the
two treatment options for either PCS or MCS score (Table 1).
A propensity matched analysis resulted in 22 patients in
each group. There were no significant differences in QoL
changes between the two groups, however, the baseline
differences in HRQoL were not significant between surgery
and SBRT, and the change in PCS score from baseline to
follow-up among surgical patients was no longer significant.
(Tables S1,S2 and Figure S2 in the supplemental appendix
online).
Among surgery patients, there were 128 who received a
lobectomy and 26 a SLR. Lobectomy patients experienced
a significant change in PCS score (−4.62, 95% CI: −6.3,
−2.93; P<0.0001) from before to after surgery, as did
SLR patients (−5.15, 95% CI: −8.84, −1.46; P=0.0081).
Lobectomy patients also experienced a significant change in
MCS score (−3.11, 95% CI: −4.74, −1.48; P=0.0002), while
the results for SLR patients were not significant (−3.12,
95% CI: −8.01, 1.80; P=0.2035) (Figure 2). There was no
significant difference between PCS and MCS scores at
baseline between the two surgery types. Patients receiving
a lobectomy were more likely to have a higher level of
education (P=0.0294) and less likely to have their baseline
and follow-up survey filled out by a proxy (P=0.0037 and
P=0.0011 respectively). Lobectomy patients were also
significantly less likely to be smokers at the time of the
follow-up survey (P=0.0032).
Both the univariate and multivariate analyses showed no
significant difference in the change over time between the
two types of surgery for either PCS or MCS score (Table 1).
Patients who underwent either SBRT (n=28) or SLR
(n=26) were compared directly. Both groups of patients
experienced a significant decline in PCS score from baseline
to follow-up, while the change for MCS scores were not
significant (Figure 3). Though not statistically significant,
there were some differences between SLR and SBRT
patients in baseline PCS score (P=0.0744) and MCS score
(P=0.0700). SLR patients were significantly more likely
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to be smokers at their baseline survey (P=0.0293), though
that difference was not present at follow-up. SBRT patients
were significantly more likely to have reported COPD,
emphysema, or asthma (P=0.0039), and angina pectoris
or CAD (P=0.0250); they were also more likely to have
diabetes (P=0.0607).
No significant differences in the change over time, as
measured by the treatment*time interaction were found in
the univariate and multivariate models for PCS score or
MCS score (Table 1).
Discussion
Confirming our hypothesis, patients from both the
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surgical and SBRT groups demonstrated decreases in
physical HRQoL, but, inconsistent with our hypothesis,
the magnitude of the decline did not vary between groups.
The only significant differences between the two groups
was in baseline physical and mental HRQoL, with SBRT
patients having worse QoL in both areas. This could be
due to the fact that the SBRT patients were likely sicker
given their significantly higher likelihood of having lungrelated comorbidities and heart disease and the fact that
they were slightly older. The decreases in mental HRQoL,
although significant for surgical patients, were quite modest
and do not represent a meaningful decline in emotional
wellbeing. This is consistent with our previous work
involving surgical patients only, in which mental HRQoL
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was relatively consistent across time points (24,34). It is
possible that, despite the decline in physical HRQoL, there
is a feeling of relief post-treatment that may counteract the
potential negative impact of physical discomfort associated
with treatment. It would be important to measure mental
HRQoL at later time points though, given that recent
qualitative research points to experiences of anxiety,
depression and isolation that can persist long after the
treatment has been completed (37).
Based on our previous work and the current findings
that suggested that lobectomy conferred a greater negative
impact on physical HRQoL as compared to SLR (34), we
compared SBRT and SLR directly, expecting that SLR
and SBRT patients would demonstrate a similar decline in
physical HRQoL as compared to SBRT patients. Support
for this hypothesis was found as there were no significant
differences between the two groups. Physical HRQoL
decreased in both groups although the rate of these
decreases was not different between the two groups. Similar
to the overall surgery group, the baseline physical and
mental HRQoL scores were slightly lower for the SBRT
group than for the SLR group, again likely due to increased
prevalence of comorbidities.
Given the small sample sizes, the results of the study
should be considered preliminary, however, the results
suggest that surgery (regardless of type) and SBRT are
relatively comparable in terms of the impact on physical and
mental HRQoL and suggest that SBRT is a good alternative
for those for whom surgery is contraindicated. The similar
impact on HRQoL was somewhat surprising given the
less invasive nature of SBRT, however it is likely that the
selection bias in terms of who receives SBRT (i.e., older,
sicker patients) may account for a greater likelihood of
experiencing slight negative physical HRQoL impacts. Also,
it is important to note that a certain percentage of patients
die during surgical treatment unlike SBRT in which death
is highly unlikely; this may have biased the sample, since
data from the sickest, most at-risk surgical patients who die
during surgery would not have been included in the study.
Study results imply that treating physicians, whether
they are surgeons or radiotherapists, need to consider the
impact of treatment on HRQoL. It is important to discuss
and prepare patients for these impacts so that social support
and post-treatment care is in place ahead of surgery. Results
from our qualitative study also suggested that coordination
with a nurse navigator or someone in a similar type of role
would be greatly beneficial to helping reduce the negative
HRQoL impacts on early-stage lung cancer patients (37).
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Strengths of this analysis are the access to the SEERMHOS data set, which allowed for the examination of
cases from a large, representative patient data pool, and the
possibility to directly compare QoL changes after surgery
and radiotherapy. A limitation, however, is that after
applying the inclusion criteria, particularly the need for
HRQoL measurement at both a pre- and post-treatment
time point, the sample size was ultimately quite reduced.
An analysis of differences at baseline between those who
completed a follow-up survey and those who did not
revealed that the latter were significantly more likely to
be treated with SBRT. Similar differences were observed
with the group who was not included due to death after
the first survey. Additionally, those who were not included
because they did not have a valid baseline or follow-up
were significantly older and also more likely to receive
SBRT than those who were included. These all point to
the possibility that the oldest and sickest patients were not
included in the current study and that they were more likely
to have been treated with SBRT. Perhaps the HRQoL
scores would have appeared even worse for the SBRT group
had these patients been included. Additionally, although
patients completed the two surveys 1 year prior and
1 year after diagnosis on average, the variability in the time
frame could impact the results. It is possible that someone
completed a HRQoL follow-up survey immediately
following surgery, and that may result in a worse HRQoL as
compared to someone who had completed the survey a year
or more after treatment. Similarly, the longer time between
diagnosis and baseline survey completion, the more likely
the patient was in better health. These factors could create
HRQoL changes that vary more as a function of time since
treatment than just time between baseline and followup. However, upon analysis, the time between surveys did
not significantly vary by treatment group (i.e., surgery
and SBRT) thereby limiting the impact that any survey
time frame variability could have on HRQoL differences
between treatment groups.
As more patients are diagnosed with early-stage lung
cancers due to increased screening, it is likely that large
databases such as such as SEER-MHOS will have more
cases with data from multiple time points. Future research
should leverage such databases, but also prospective studies
of early-stage lung cancer treatment impacts are needed
to truly understand and differentiate effects on HRQoL.
Further, measurement should extend beyond QoL to also
include more specific measures of physical health such as
pain and sleep and more specific measures of mental health
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such as anxiety and depression. It is possible that using more
refined and specific tools will elucidate greater treatment
differences that will ultimately inform treatment decisionmaking for early-stage lung cancer patients.
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Supplementary

SEER-MHOS Lung Cancer Records
n=16,771

Excluded:
Lung cancer not first primary (n=3,919);
Missing record before treatment (n=3,190);
Missing record after treatment (n=8,962);
Gap >2.5 years in survey records (n=82)

Excluded:
Cancer not microscopically confirmed (n=35);
Not stage 0 or I at diagnosis (n=380)

Survey records before and after treatment
n=618

Excluded:
Underwent multiple treatments or no
treatment (n=19)

Patients with stage 0 or I
n=203

Sample size:
Patients with only surgery or SBRT n=184

Figure S1 Selection criteria. SEER-MHOS, Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey; SBRT,
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Figure S2 Change over time in PCS and MCS scores in surgery and SBRT groups, propensity matched cohort (n=44). PCS, Physical
Component Score; MCS, Mental Component Score; SBRT, stereotactic body radiation therapy; Srg, surgery.

Table S1 Comparison of surgical and SBRT groups before and after propensity matching on demographics
P value
Variable
Before propensity matching

After propensity matching*

Age at diagnosis

0.2080

0.8840

Gender

0.9217

0.7055

Race

0.9739

1.0000

Education

0.1590

0.4795

Smoking status

0.1086

0.3173

Survey completed by proxy

0.7357

0.5271

COPD/emphysema/asthma

<0.0001

0.3173

Angina pectoris/CAD

0.0108

0.4797

Before propensity matching, n=184 (156 surgery, 28 SBRT); After propensity matching, n=44 (22 surgery, 22 SBRT). *, matched on age
at diagnosis, gender, race, education, smoking status, whether the baseline survey was completed by proxy, and presence of COPD/
emphysema/asthma, and angina pectoris/CAD. COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PCS,
Physical Component Summary; MCS, Mental Component Summary; SBRT, stereotactic body radiation therapy.

Table S2 Comparison of surgical and SBRT groups before and after propensity matching on baseline QoL
Quality of
life

Before propensity matching, mean (SD)

After propensity matching*, mean (SD)

Surgery

SBRT

P value

Surgery

SBRT

P value

PCS

39.6 (11.8)

32.9 (10.2)

0.0061

32.5 (13.9)

33.6 (10.8)

0.7628

MCS

52.3 (10.0)

43.8 (14.4)

0.0056

51.2 (11.0)

45.1 (14.9)

0.1553

Before propensity matching, n=184 (156 surgery, 28 SBRT); After propensity matching, n=44 (22 surgery, 22 SBRT). *, matched on age
at diagnosis, gender, race, education, smoking status, whether the baseline survey was completed by proxy, and presence of COPD/
emphysema/asthma, and angina pectoris/CAD. COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PCS,
Physical Component Summary; MCS, Mental Component Summary; SBRT, stereotactic body radiation therapy; SD, standard deviation.

